Synthroid vs Armour Thyroid Side-Effect Profile Head-to-Head

What Are These Two Medications?

Synthroid is the brand name for levothyroxine sodium, a synthetic T4-only thyroid hormone replacement. Armour Thyroid is desiccated porcine thyroid gland standardized to contain 38 mcg T4 and 9 mcg T3 per 60 mg grain. That T3 component is the reason the two drugs behave differently in the body and produce a partly different side-effect profile.

Mechanism of Action

Levothyroxine delivers T4, which peripheral tissues convert to the active hormone T3 through deiodinase enzymes. The conversion rate varies by individual genetics, gut health, and concurrent medications [1]. Armour Thyroid skips this conversion step for roughly one-quarter of its thyroid hormone content, delivering T3 directly into the bloodstream.

Why the Fixed T4:T3 Ratio Matters

In humans, the thyroid secretes T4 and T3 in an approximately 14:1 ratio. Armour Thyroid's 4:1 T4:T3 ratio is physiologically supraphysiologic in T3. After a dose, serum T3 peaks sharply within 2 to 4 hours, then falls. This peak-and-trough pattern does not occur with levothyroxine monotherapy and is the source of most T3-specific side effects [2].

Shared Side Effects: What Both Drugs Can Cause

Both medications produce the same side effects when the dose is too high, because both ultimately raise serum T3. The American Thyroid Association's 2014 guidelines on hypothyroidism management note that "the risks of T4/T3 combination therapy include the potential for iatrogenic hyperthyroidism and cardiac arrhythmia" [1]. Those same risks apply to levothyroxine monotherapy when over-dosed.

Cardiovascular Effects

Palpitations and tachycardia are the most frequently reported cardiovascular complaints with either drug. A 2019 meta-analysis published in JAMA Internal Medicine found that suppressed TSH (below 0.1 mIU/L) was associated with a 2.8-fold increased risk of atrial fibrillation regardless of which thyroid preparation caused the suppression [3]. Heart rate can rise even when TSH remains in range if free T3 is not measured.

Musculoskeletal and Bone Effects

Chronic over-replacement with either agent reduces bone mineral density. Postmenopausal women on suppressive levothyroxine doses lose lumbar spine BMD at approximately 1% per year [4]. Armour Thyroid carries the same risk. The key variable is TSH, not the drug itself.

Central Nervous System Effects

Anxiety, insomnia, irritability, and tremor occur with both medications when serum T3 rises above the mid-normal range. These symptoms are dose-dependent and typically resolve with dose reduction.

Side Effects Specific to Armour Thyroid (NDT)

The T3 content of Armour Thyroid creates a distinct risk profile absent from levothyroxine monotherapy at equivalent thyroid-stimulating hormone (TSH) targets.

Acute T3 Peak Symptoms

Within 1 to 4 hours of taking Armour Thyroid, serum free T3 can rise transiently above the normal reference range even when the 24-hour average T3 remains acceptable [2]. Patients often describe this as a brief surge of heart racing, flushing, or anxiety that peaks mid-morning and resolves by afternoon. Splitting the daily dose into twice-daily administration attenuates this peak.

Cardiovascular Load

The direct T3 spike after each dose increases cardiac oxygen demand acutely. In patients with pre-existing coronary artery disease or uncontrolled hypertension, this transient T3 elevation may be clinically meaningful. The 2014 ATA guidelines state: "Patients with cardiac disease may be particularly vulnerable to the adverse effects of T3" [1].

Adrenal Interaction

Rapid T3 delivery can increase cortisol clearance. Patients with undiagnosed adrenal insufficiency may experience adrenal crisis-like symptoms after starting Armour Thyroid. This interaction is not reported with slow T4 titration.

Side Effects Specific to Levothyroxine (Synthroid)

Levothyroxine carries its own set of issues distinct from those tied to desiccated thyroid.

Conversion Impairment

Patients with polymorphisms in the DIO2 gene (deiodinase type 2), estimated to affect 12 to 16% of the population, convert T4 to T3 less efficiently [5]. For these patients, adequate TSH suppression with levothyroxine may not normalize intracellular T3 levels, leaving hypothyroid symptoms despite "normal" labs. This is not a side effect in the traditional sense, but it does lead to over-dosing attempts that then produce hyperthyroid side effects.

Absorption Interactions

Levothyroxine absorption is highly sensitive to co-administration. Calcium carbonate, iron supplements, proton pump inhibitors, and cholestyramine each reduce absorption by 20 to 40%, forcing dose escalation and increasing the risk of inadvertent over-replacement when those agents are later stopped [6]. Armour Thyroid has the same absorption concerns for its T4 fraction, though the clinical literature on NDT interactions is thinner.

Inactive Ingredient Reactions

Synthroid tablets contain lactose monohydrate, corn starch, and acacia. Patients with diagnosed lactose intolerance or corn sensitivities occasionally report gastrointestinal discomfort. A lactose-free levothyroxine formulation (Tirosint) is available as an alternative.

Head-to-Head Evidence: The Hoang 2013 Trial

The most cited direct comparison is Hoang et al., published in Journal of Clinical Endocrinology and Metabolism in 2013 (N=70, crossover design, 16 weeks per arm) [2]. Participants were randomized to either NDT (Armour Thyroid) or levothyroxine titrated to equivalent TSH targets.

Primary Findings on Side Effects

The two drugs produced statistically similar TSH levels (P<0.05 was not reached for TSH difference between groups). Thyroid symptom scores on the validated Thyroid Symptom Questionnaire did not differ significantly between arms. No serious adverse events were attributed to either medication.

Patient Preference Data

Despite equivalent symptom scores, 49% of participants preferred NDT at the study's end versus 19% who preferred levothyroxine, with 32% expressing no preference [2]. Patients on NDT lost a mean of 4 lb (1.8 kg) more than those on levothyroxine over the 16-week period. The authors attributed this to the T3-mediated increase in resting metabolic rate, though they cautioned that the weight difference may not persist long-term.

Limitations of Hoang 2013

The sample was small. Participants were relatively healthy adults without significant comorbidities. The results may not generalize to patients with atrial fibrillation, osteoporosis, or adrenal co-morbidities where the T3 peak of NDT carries more risk.

ATA Guideline Position and Current Standard of Care

The 2014 American Thyroid Association guidelines on hypothyroidism management conclude that "levothyroxine should remain the standard of care for treating hypothyroidism" [1]. The recommendation is graded on the basis of long-term safety data, dosing consistency, and a large evidence base built over decades.

The ATA does not categorically prohibit NDT. The guidelines acknowledge that "data from a recent trial suggest that some patients may prefer the combination preparation," referring in part to the Hoang 2013 findings [1]. Prescribers willing to offer NDT are advised to inform patients about the supraphysiologic T3 ratio, the lack of long-term cardiovascular safety data, and the potential for batch-to-batch potency variability in desiccated thyroid preparations.

Monitoring Differences

Patients on levothyroxine are monitored with TSH alone in stable hypothyroidism, per standard practice. Patients on Armour Thyroid benefit from free T3 measurement in addition to TSH, because TSH can be low-normal while free T3 peaks above range transiently. A free T3 drawn 2 to 4 hours post-dose captures the peak; a trough draw before the next dose captures the nadir. Neither single time-point reflects true daily average T3 exposure.

Dosing and Conversion Between Agents

Switching from one agent to the other requires careful dose conversion. The most widely referenced equivalence is 60 mg (1 grain) of Armour Thyroid equals approximately 100 mcg of levothyroxine. This approximation holds for the T4 component but does not account for the added T3, which means most patients transitioning to Armour Thyroid need a lower T4-equivalent dose to avoid over-replacement [1].

Starting the Switch

Clinicians typically reduce the levothyroxine equivalent dose by 20 to 25% when converting to NDT to account for the direct T3 contribution. TSH should be rechecked 6 to 8 weeks after any dose change. Free T3 should be checked at the same interval in patients reporting palpitations, anxiety, or unexplained weight loss.

Going Back to Levothyroxine

Patients switching from Armour Thyroid back to levothyroxine may experience a transient period of relative hypothyroidism lasting 1 to 3 weeks while peripheral T4-to-T3 conversion re-establishes. Symptom diaries during this transition help distinguish conversion lag from true inadequate dosing.

Special Populations and Risk Stratification

Not every patient is an equal candidate for either drug. Clinical context changes the benefit-risk calculation substantially.

Cardiac Patients

The transient T3 peak with Armour Thyroid is a meaningful concern in patients with recent myocardial infarction, unstable angina, or paroxysmal atrial fibrillation. In these populations, levothyroxine's predictable serum profile and absence of T3 peaks makes it the safer choice. The ACC/AHA do not specifically address thyroid preparation choice, but cardiologists routinely request levothyroxine-only therapy for patients on anti-arrhythmic medications [3].

Postmenopausal Women and Bone Health

Bone loss from suppressed TSH is identical regardless of the thyroid preparation used. Postmenopausal women should have TSH kept at or above 0.5 mIU/L unless thyroid cancer management requires suppression [4]. This constraint applies to both Synthroid and Armour Thyroid equally.

Patients with DIO2 Polymorphisms

The subset of patients with DIO2 polymorphisms may theoretically benefit from exogenous T3. One genome-wide study in approximately 9,000 participants found that DIO2 Thr92Ala homozygotes reported worse psychological well-being on levothyroxine monotherapy compared to heterozygotes or wild-type individuals [5]. Adding T3 through Armour Thyroid or T3/T4 combination therapy is a rational consideration in this group, provided cardiac risk is low.

Pregnancy

Neither Armour Thyroid nor any T3-containing preparation is recommended in pregnancy. T3 does not cross the placenta in meaningful amounts, but the supraphysiologic T3 doses from NDT can suppress maternal TSH, and TSH suppression in the first trimester is associated with adverse fetal outcomes [7]. Levothyroxine is the standard and preferred agent for all pregnant patients with hypothyroidism.

Cost, Availability, and Practical Considerations

Levothyroxine is one of the most prescribed drugs in the United States and is available as a generic at all pharmacies. A 90-day supply of 100 mcg levothyroxine costs between $10 and $20 at most retail chains. Armour Thyroid is a brand-name product with no true bioequivalent generic in the United States; a 90-day supply of 60 mg typically costs $60 to $120 without insurance.

Armour Thyroid has faced periodic supply shortages due to its reliance on porcine thyroid gland sourcing and FDA manufacturing requirements. Patients should be counseled on contingency plans before starting NDT long-term. A comparable desiccated thyroid product, NP Thyroid (Acella Pharmaceuticals), provides an alternative if Armour becomes unavailable, though prescribers should note these are not automatically interchangeable without TSH recheck [8].

Summary of Side-Effect Differences by Category

| Side Effect Category | Levothyroxine (Synthroid) | Armour Thyroid (NDT) | |---|---|---| | Palpitations from over-dose | Yes | Yes | | Acute post-dose T3 peak symptoms | No | Yes (peaks at 2 to 4 hours) | | Anxiety/insomnia from T3 | Only if over-dosed | Can occur at replacement doses | | Bone loss | Yes (if TSH suppressed) | Yes (if TSH suppressed) | | AF risk | Yes (if TSH suppressed) | Yes, plus acute T3 load | | Adrenal interaction | Minimal | Possible with rapid T3 rise | | Absorption interference | Significant (20 to 40%) | Similar for T4 fraction | | Gastrointestinal (inactive ingredients) | Lactose, corn starch | Desiccated porcine gland |